Abstract:Prion diseases are caused by the conversion of normal cellular prion proteins (PrP) into lethal prion aggregates. These prion aggregates are composed of proteinase K (PK) resistant fibrils and comparatively PK-sensitive oligomers. Currently there are no anti-prion pharmaceuticals available to treat or prevent prion disease. Methods of discovering anti-prion molecules rely primarily on relatively complex cell-based, tissue slice or animal-model assays that measure the effects of small molecules on the formation of PK-resistant prion fibrils. These assays are difficult to perform and do not detect the compounds that directly inhibit oligomer formation or alter prion conversion kinetics. We have developed a simple cell-free method to characterize the impact of anti-prion fibril compounds on both the oligomer and fibril formation. In particular, this assay uses shaking-induced conversion (ShIC) of recombinant PrP in a 96-well format and resolution enhanced native acidic gel electrophoresis (RENAGE) to generate, assess and detect PrP fibrils in a high throughput fashion. The end-point PrP fibrils from this assay can be further characterized by PK analysis and negative stain transmission electron microscopy (TEM). This cell-free, gel-based assay generates metrics to assess anti-prion fibril efficacy and kinetics. To demonstrate its utility, we characterized the action of seven well-known anti-prion molecules: Congo red, curcumin, GN8, quinacrine, chloropromazine, tetracycline, and TUDCA (taurourspdeoxycholic acid), as well as four suspected anti-prion compounds: trans-resveratrol, rosmarinic acid, myricetin and ferulic acid. These findings suggest that this in vitro assay could be useful in identifying and comprehensively assessing novel anti-prion fibril compounds. Abbreviations: PrP, prion protein; PK, proteinase K; ShIC, shaking-induced conversion; RENAGE, resolution enhanced native acidic gel electrophoresis; TEM, transmission electron microscopy; TUDCA, taurourspdeoxycholic acid; BSE, bovine spongiform encephalopathy; CWD, chronic wasting disease; CJD, Creutzfeldt Jakob disease; GSS, Gerstmann-Sträussler-Scheinker syndrome; FFI, fatal familial insomnia; PrPc, cellular prion protein; recPrPC, recombinant monomeric prion protein; PrPSc, infectious particle of misfolded prion protein; RT-QuIC, real-time quaking-induced conversion; PMCA, Protein Misfolding Cyclic Amplification; LPS, lipopolysaccharide; EGCG, epigallocatechin gallate; GN8, 2-pyrrolidin-1-yl-N-[4-[4-(2-pyrrolidin-1-yl-acetylamino)-benzyl]-phenyl]-acetamide; DMSO, dimethyl sulfoxide; ScN2A, scrapie infected neuroblastoma cells; IC50, inhibitory concentration for 50% reduction; recMoPrP 23-231, recombinant full-length mouse prion protein residues 23-231; EDTA; PICUP, photo-induced cross-linking of unmodified protein; BSA, bovine serum albumin;; PMSF, phenylmethanesulfonyl fluoride.

Copper(II) Inhibits in Vitro Conformational Conversion of Ovine Prion Protein Triggered by Low Ph.

Copper coordination modulates prion conversion and infectivity in mammalian prion proteins

Copper binding alters the core structure of amyloid fibrils formed by Y145Stop human prion protein

Comparison of the Unfolding and Oligomerization of Human Prion Protein under Acidic and Neutral Environments by Molecular Dynamics Simulations

Infection of Prions and Treatment of PrP106–126 Alter the Endogenous Status of Protein 14-3-3 and Trigger the Mitochondrial Apoptosis Possibly via Activating Bax Pathway

Discovery of small molecules binding to the normal conformation of prion by combining virtual screening and multiple biological activity evaluation methods

Cellular Prion Protein Acquires Resistance to Proteolytic Degradation Following Copper Ion Binding

Experimental and Theoretical Insights into the Inhibition Mechanism of Prion Fibrillation by Resveratrol and Its Derivatives

Mutant D178N Prion Protein Converts Spontaneously in RT-QuIC Assay

Copper and Zinc Binding Modulates the Aggregation and Neurotoxic Properties of the Prion Peptide Prp106-126

Preventing misfolding of the prion protein by trimethylamine N-oxide

Manganese-induced Changes of the Biochemical Characteristics of the Recombinant Wild-Type and Mutant PrPs

A High “Steaks” Molecular Story: Copper Interactions with Mad Cow Disease Prion Proteins

The Octarepeat Region of Hamster PrP (Prp51-91) Enhances the Formation of Microtubule and Antagonize Cu(2+)-induced Microtubule-Disrupting Activity.

Glycan chains modulate prion protein binding to immobilized metal ions

Quiescin-sulfhydryl oxidase inhibits prion formation in vitro

Structural and Dynamical Mechanisms of a Naturally Occurring Variant of the Human Prion Protein in Preventing Prion Conversion?

A simple in vitro assay for assessing the efficacy, mechanisms and kinetics of anti-prion fibril compounds

Effects of the Pathogenic Mutation A117V and the Protective Mutation H111S on the Folding and Aggregation of PrP106-126: Insights from Replica Exchange Molecular Dynamics Simulations.

Metal Ions Bound to Prion Protein Affect its Interaction with Plasminogen Activation System

Binding of Copper Ions with Octapeptide Region in Prion Protein: Simulations with Charge Transfer Model